Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
Antiviral treatment of HCV in thalassemia has raised concerns of ribavirin-induced hemolysis
and increased iron loading. Blood Transfusion in Thalassemic patients are a known high risk
for acquiring hepatitis C. The investigators are trying the PEGASYS (Peginterferon
alpha-2a(40 KD)) plus Ribavirin in Thalassemic patients with HCV.
Phase:
Phase 4
Details
Lead Sponsor:
Baqiyatallah Medical Sciences University
Collaborators:
Baqiyatallah Research Center for Gastroenterology and Liver Diseases Guilan Research Center for Gastroenterology and Liver Diseases Guilan University of Medical Sciences Tabriz Research Center for Gastroenterology and Liver Diseases Tehran Hepatitis Center